The FDA is soliciting applications for a Critical Path program that will focus on cardiovascular drug safety and biomarker research.
According to a recent notice, the FDA will consider a single source application for awarding a cooperative agreement. The agency anticipates providing up to $750,000 in fiscal 2006 to support the research program, which will include the development of an infrastructure supporting related studies in cardiovascular disease and genomic/proteomic biomarker research.
An additional two years of support -- up to $750,000 per year -- may be provided depending on the availability of federal funds and the success of the program.
For more information, access http://www.fda.gov/OHRMS/DOCKETS/98fr/oc0644-n000001.pdf (http://www.fda.gov/OHRMS/DOCKETS/98fr/oc0644-n000001.pdf).